Cite
423P Fruquintinib plus sintilimab in refractory repair-proficient (pMMR)/microsatellite stable (MSS) metastatic colorectal cancer (mCRC): Preliminary clinical results and biomarker analyses from a phase II study.
MLA
Zhang, W., et al. “423P Fruquintinib plus Sintilimab in Refractory Repair-Proficient (PMMR)/Microsatellite Stable (MSS) Metastatic Colorectal Cancer (MCRC): Preliminary Clinical Results and Biomarker Analyses from a Phase II Study.” Annals of Oncology, vol. 33, Sept. 2022, p. S728. EBSCOhost, https://doi.org/10.1016/j.annonc.2022.07.561.
APA
Zhang, W., Sun, Y., Jiang, Z., Liu, T., Gong, C., Yang, L., Xin, Y., Huang, D., & Zhou, A. (2022). 423P Fruquintinib plus sintilimab in refractory repair-proficient (pMMR)/microsatellite stable (MSS) metastatic colorectal cancer (mCRC): Preliminary clinical results and biomarker analyses from a phase II study. Annals of Oncology, 33, S728. https://doi.org/10.1016/j.annonc.2022.07.561
Chicago
Zhang, W., Y. Sun, Z. Jiang, T. Liu, C. Gong, L. Yang, Y. Xin, D. Huang, and A. Zhou. 2022. “423P Fruquintinib plus Sintilimab in Refractory Repair-Proficient (PMMR)/Microsatellite Stable (MSS) Metastatic Colorectal Cancer (MCRC): Preliminary Clinical Results and Biomarker Analyses from a Phase II Study.” Annals of Oncology 33 (September): S728. doi:10.1016/j.annonc.2022.07.561.